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Abstract The cocktail approach is an advantageous strategy
used to monitor the activities of several cytochromes P450
(CYPs) in a single test to increase the throughput of in vitro
phenotyping studies. In this study, a cocktail mixture was
developed with eight CYP-specific probe substrates to simul-
taneously evaluate the activity of the most important CYPs,
namely, CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2C19,
CYP2D6, CYP2E1, and the CYP3A subfamily. After cocktail
incubation in the presence of human liver microsomes
(HLMs), the eight selected substrates and their specific me-
tabolites were analyzed by ultra-high-pressure liquid chroma-
tography and electrospray ionization quadrupole time-of-
flight mass spectrometry. Qualitative and quantitative data
were simultaneously acquired to produce an overview of the
extended phase I biotransformation routes for each probe
substrate in the HLMs and to generate phenotypic profiles of
various HLMs. A comparison of the cocktail strategy with an
individual substrate assay for each CYP produced similar
results. Moreover, the cocktail was tested on HLMs with
different allelic variants and/or in the presence of selective
inhibitors. The results were in agreement with the genetic
polymorphisms of the CYPs and the expected effect of the
alterations. All of these experiments confirmed the reliability
of this cocktail assay for phenotyping of the microsomal
CYPs.
Keywords Cocktail approach . Ultra-high-pressure liquid
chromatography–quadrupole time-of-flight mass
spectrometry . Cytochrome P450 profile . Phenotyping .
Genetic polymorphism . Human liver microsomes
Introduction
Cytochromes P450 (CYPs) are the major phase I metabolic
enzymes involved in the biotransformation of xenobiotics and
endogenous compounds [1]. The activity of CYPs is character-
ized by a high interindividual variability due to environmental
factors (e.g., diet, drug therapy, toxic substances) and/or genetic
polymorphisms, which are part of the individual CYP pheno-
type. Certain major isoforms of the CYP superfamily involved
in the metabolism of marketed drugs—CYP2C9, CYP2C19,
and CYP2D6—are recognized as highly polymorphic. Accord-
ing to the type of allelic variant affecting these CYPs, genetic
polymorphism can significantly alter their metabolic activity,
thus modifying the clinical response and/or increasing the risk
of drug–drug interactions (DDI). The evaluation of genetic
polymorphism can be performed by sequencing the DNA of
the CYP genes (genotyping) or by determining the CYP
expression/activity (phenotyping). In certain cases, owing to
the genetic and epigenetic regulations, the relationship between
the CYP gene and the enzymatic activity is not trivial, which
makes the test selection (e.g., constitutional or functional) for
predicting the drug’s clinical response difficult. However, the
evaluation of the DDI is possible only by CYP phenotyping [2].
Currently, in vitro phenotyping of CYPs has been success-
fully used to enhance the background understanding of the
behavior of polymorphic CYPs involved in xenobiotic metab-
olism and DDI. For this purpose, human liver microsomes
(HLMs) are typically used as the in vitro native phase I enzyme
source for metabolism studies owing to their simple prepara-
tion and ease of handling and the commercial availability of
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numerous allelic variants. New strategies for performing in vitro
metabolism studies have been developed recently with a particu-
lar focus on inexpensive automation and reduction of reagent
consumption [3, 4]. High-throughput strategies for microsomal
CYP investigations based on liquid chromatography (LC)–mass
spectrometry (MS) have been developed with regard to its pow-
erful separation capabilities, including high sensitivity, selectivity,
and resolution [5, 6]. Among these strategies, the cocktail ap-
proach has been developed recently to efficiently and rapidly
monitor the activities of several CYPs within a single test. In this
study, selective CYP substrates, called probes, are incubated with
microsomes, consecutively reducing the time and assay costs.
Several in vitro cocktail approaches have been reported in the
literature with various numbers of probe substrates and analytical
strategies. The current status of cocktail approaches and methods
to investigate CYP activities in HLMs has been reviewed recently
[7]. In the context of phenotyping of CYPs, the use of a high-
resolution device, such as a quadrupole time-of-flight (QTOF)
mass spectrometer, is appealing considering that oneCYP is often
involved in the formation of numerousmetabolites.With this type
of instrumentation, untargeted acquisition provides an extended
phenotypic profile of the CYPs. Hence, the substrates and their
expected and unexpected metabolites are sensitively and accu-
rately detected and identified within a single run. An additional
advantage of this instrumentation is that data can be handled,
processed, and filtered after the acquisition with specific commer-
cially available software for untargeted metabolite detection and/
or identification. Therefore, the QTOF instrument could present
several benefits for in vitro CYP phenotyping investigations.
In this study, a cocktail assay was originally designed for the
phenotyping of the most important CYPs in humans, namely,
CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2C19, CYP2D6,
CYP2E1, and the CYP3A subfamily. An LC–MSEmethod using
generic gradient conditions was developed on an ultra-high-
pressure LC (UHPLC)–QTOF platform for the reliable quantita-
tive and qualitative analysis of this cocktail metabolization. The
CYP activity assessment was based on the metabolic ratio. A
radar plot representation of the CYP phenotypic profile was
proposed for a better comparison of the different assays and the
various phenotypes determined. A comparison was made be-
tween the cocktail approach and classic tests, which perform
individual incubations of the substrates. The latter was then
evaluated for the CYP phenotyping of allelic variant HLMs.
An altered allelic variant HLM was finally evaluated by addition
of CYP-specific inhibitors and human recombinant enzymes.
Materials and methods
Chemicals, reagents, test compounds, and other materials
Methanol (MeOH), acetonitrile (ACN), and water of ultra LC–
MS grade were purchased from Biosolve (Valkenswaard,
Netherlands). Formic acid (98–100 %) was obtained fromMerck
(Darmstadt, Germany). Chlorzoxazone (98 %), 6-
hydroxychlorzoxazone (97 %), (±)-4′-hydroxymephenytoin
(98 %), 4′-hydroxyflurbiprofen (98 %), and hydroxybupropion
(95 %) were purchased from Toronto Research Chemicals (To-
ronto ON, Canada). Potassium hydroxide, 4-(2-
hydroxyethyl)piperazine-1-ethanesulfonic acid sodium salt
(HEPES) (99.5 %), dextromethorphan hydrobromide (99 %),
dextrorphan tartrate (98 %), bupropion hydrochloride (98 %),
phenacetin (97 %), acetaminophen (99 %), flurbiprofen (99 %),
coumarin (99 %), 7-hydroxycoumarin (99 %), ketoconazole
(98 %), and anhydrous quinidine (98 %) were obtained from
Sigma-Aldrich (Buchs, Switzerland), whereas methanolic stock
solutions of midazolam and 1-hydroxymidazolam were pur-
chased from Lipomed (Arlesheim, Switzerland). (S)-
Mephenytoin (99 %) was obtained from Enzo Life Sciences
(Lausen, Switzerland), reduced β-nicotinamide adenine dinucle-
otide 2′-phosphate tetrasodium salt (NADPH) (96%) was obtain-
ed from Applichem (Darmstadt, Germany), and leucine-
enkephalinwas obtained fromBachem (Bubendorf, Switzerland).
Pooled HLMs from 30 donors (i.e., reference HLMs) and HLMs
with allelic variants (CYP2D6*4/*4, CYP2C9*3/*3, and
CYP2C19*2/*2) from single donors (HH35, HH519, and
HH689, respectively) were purchased from BD Biosciences
(Allschwil, Switzerland). Human CYP Baculosomes reagent
(baculosome CYP2D6) was obtained from Invitrogen (Basel,
Switzerland). Aliquots of HLMs and baculosome CYP2D6 were
stored at −80 °C. A 50mMNADPH stock solution was prepared
in water and stored at −20 °C. Immediately before the CYP-
dependent metabolism assays, intermediate concentrations of the
HLMs and baculosome CYP2D6 were prepared by diluting
aliquots with the 50 mMHEPES (pH 7.4) buffer solution, which
was prepared by dissolving the required amount of HEPES in
water. The pH was adjusted to 7.4 with potassium hydroxide
using a SevenMulti S40 pH meter (Mettler Toledo, Greifensee,
Switzerland). The substrate, metabolite, and inhibitor stock solu-
tions at 1 mg/mL were prepared in MeOH and stored at −20 °C
for 6 months or less. Intermediate solutions were appropriately
reconstituted daily in the 50mMHEPES (pH 7.4) buffer solution.
Characterization of CYP-dependent metabolism in HLMs
Incubation method
All of the microsomal incubations were performed in dupli-
cate in a final incubation volume of 100 μL. The reaction
medium contained 50 mMHEPES (pH 7.4), excess NADPH,
0.5 mg protein per milliliter of HLMs, and an individual CYP
probe substrate or a cocktail of substrates. The final substrate
concentrations were obtained by adding the required volume
of the intermediate substrate or cocktail solution to the reac-
tion medium. These concentrations were as follows: 50 μM
for phenacetin, 2 μM for coumarin, 5 μM for bupropion,
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5 μM for flurbiprofen, 100 μM for (S)-mephenytoin, 5 μM for
dextromethorphan, 40 μM for chlorzoxazone, and 2.5 μM for
midazolam. The final organic solvent (MeOH) concentration
was 0.5 % (v/v). After preincubation for 3 min at 37 °C, the
CYP-dependent phase I reactions were initiated by adding
excess NADPH (2.0 mM). The incubation proceeded for
20 min at 37 °C under agitation (400 rpm). The enzymatic
reaction was stopped by adding 100 μL of ice-cold ACN to
the reaction medium. The precipitated proteins were removed
by centrifugation (5 min at 10,000 rpm), and an aliquot
(150 μL) of the resulting supernatant was transferred to a vial
for LC–MS analysis.
Well-characterized CYP competitive inhibitors, such as
quinidine (CYP2D6) and ketoconazole (CYP3A), were added
at a single concentration of 1 μM, whereas baculosome
CYP2D6 was tested at 3 nM. Each reagent was incubated in
duplicate with the cocktail of substrates and the allelic variant
CYP2D6*4/*4 HLMs under the previously described incuba-
tion conditions.
Data treatment
Prism version 5.01 (GraphPad Software, San Diego, CA,
USA) was used to determine the most appropriate fitting
model for the depletion of the eight substrates (one phase
decay) and the formation of the eight metabolites (one site
total).
Liquid chromatography–mass spectrometry
UHPLC–QTOF instrumentation
The chromatographic analyses were performed with an
Acquity UPLC system (Waters, Milford, MA, USA) able to
deliver mobile phases at a pressure of up to 1,000 bar. The
equipment includes a binary solvent manager with a maxi-
mum delivery flow rate of 2 mL/min, an autosampler with a
2-μL loop operating in full-loop injection mode, and a column
manager composed of a precolumn eluent heater and a column
oven set to 40 °C. The UPLC system was coupled in an
optimized configuration with a Xevo® QTOFmass spectrom-
eter (Waters, Milford, MA, USA) fitted with a Z-spray
electrospray ionization (ESI) source [8]. The samples were
stored at 4 °C in the autosampler prior to and during the
analysis. Data acquisition, data handling, and instrument con-
trol were performed by MassLynx version 4.1 (Waters, Mil-
ford, MA, USA).
Reversed-phase LC conditions
The reversed-phase LC separations were performed on a
Waters 100 mm×2.1 mm XBridgeTM BEH C18 XP column
with 2.5-μm particle size and a flow rate of 400 μL/min in
gradient mode (solvent A, water with 0.1 % formic acid;
solvent B, ACN with 0.1 % formic acid, 2–75 % solvent B
in 15 min, up to 95 % solvent B in 0.2 min, held at 95 %
solvent B to 0.5 min, then column reconditioning at 2 %
solvent B to 18 min), with the eluate from the first 0.5 min
diverted to waste.
ESI-QTOF-MSE parameters
Regarding the MS operating conditions, the desolvation
gas (nitrogen) flow was set to 1,000 L/h with a tem-
perature of 500 °C, the source temperature was 150 °C,
the cone gas (nitrogen) flow rate was 20 L/h, the
collision gas (argon) flow rate was 0.2 mL/min, and
the capillary voltage was 3.0 kV in the positive mode
and 2.4 kV in the negative mode. The cone voltage and
the extraction cone voltage were similar in both positive
and negative mode at 30 V and 4.1 V, respectively. The
microchannel plates were operated at 2,200 V in posi-
tive mode and at 1,750 V in negative mode, with a 4-
GHz time-to-digital converter. The QTOF-MS system
was operated in wide-pass quadrupole mode with a
low collision energy set to 4 eV to acquire MS infor-
mation in the first function, and a collision energy ramp
from 20 to 35 eV was applied in the second function
(MSE mode). The data were collected in the V-optics
centroid mode over an m/z range of 100–1,000 for both
functions with an accumulation time of 0.2 s. The data
were acquired using programmed dynamic range en-
hancement (pDRE) technology and an independent ref-
erence lock-mass ion infused through the LockSpray™
interface to ensure accuracy and to decrease acquisition
variability. A solution of leucine-enkephalin (m/z
556.2771) at a concentration of 0.2 μg/mL in 1:1
(v/v) ACN/water plus 0.1 % formic acid was used as
the reference compound and was infused at a flow rate
of 10 μL/min. The LockSpray frequency was set to
20 s (scan duration of 1 s) and the data were averaged
over five spectra.
Quantitative evaluation of the method
Selectivity
Method selectivity was assessed by injecting (1) HEPES
buffer, (2) the analyte and cofactor in HEPES buffer, (3) a
blank microsomal incubation medium with the cofactor, (4)
the analyte in blank microsomal incubation medium without
the cofactor, and (5) a mixture of analytes in microsomal
incubation medium without the cofactor. Extracted ion chro-
matograms for each analyte were used to assess potential
interference at the corresponding retention time.
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Response function linearity
The response function for the eight substrates and their me-
tabolites (N=16) was evaluated using microsomal incubation
mixtures (without cofactor) reconstituted at concentrations
ranging from 1 to 5,000 ng/mL. To evaluate the response
function of each specific transition, each analyte in ten con-
centrations (k=10) injected in triplicate was investigated. A
conventional least-squares linear regression without
weighting was fitted to the data obtained, and the response
function range was evaluated with a determination coefficient
(R2) higher than 0.95.
Limit of detection and lower limit of quantification
The limit of detection and the lower limit of quantification
were measured in reconstituted incubation samples as the
concentrations possessing a response with a signal-to-noise
ratio greater than or equal to 3 and 10, respectively.
Matrix effect
The matrix effect was determined according to method de-
scribed byMatuszeski et al. [9]. Briefly, the signal intensity of
the sample including the mixture of eight substrates and their
metabolites added at three different concentrations (low,
50 ppb; medium, 200 ppb; high, 500 ppb) to reconstituted
incubation mixture was compared with that of the standard
mixture solution.
Precision and stability
The precision of the analytical method was measured by
triplicate injection of reconstituted microsomal mixtures of
substrates and metabolites on different analysis days. The
eight substrate and metabolite pairs were evaluated at half
concentration of the substrate during incubation. The relative
standard deviation obtained on the absolute peak area and the
quadratic mean (or root mean square) were used for assess-
ment of within-day and between-day variabilities, respective-
ly. The stability of the overall bioanalytical process was eval-
uated by testing different aliquots of pooled HLMs on differ-
ent days.
Results and discussion
Selection of substrates and evaluation of the reaction
conditions
The eight CYP probe substrates of the cocktail, namely,
phenacetin (CYP1A2), coumarin (CYP2A6), bupropion
(CYP2B6), flurbiprofen (CYP2C9), (S)-mephenytoin
(CYP2C19), dextromethorphan (CYP2D6), chlorzoxazone
(CYP2E1), and midazolam (CYP3A subfamily), were select-
ed to monitor simultaneously the metabolic activities of clin-
ically and toxicologically relevant cytochromes in humans. In
preliminary experiments, several well-characterized probes
were tested for an optimal cocktail assay. These eight com-
pounds were finally selected according to the following: (1)
in vitro recommendations based on the specificity of the CYP
probe reaction (e.g., coumarin, bupropion, dextromethorphan,
chlorzoxazone, and midazolam) [10], (2) in vivo and in vitro
considerations (e.g., flurbiprofen), and (3) analytical and met-
abolic issues. Phenacetin for example, was preferred over
caffeine owing to its higher microsomal metabolic rate at a
low concentration, (S)-mephenytoin was retained for the
CYP2C19 activity assessment because omeprazole was found
to be degraded in acidic solution, and flurbiprofen was
retained over the commoner CYP2C9 in vitro probes, such
as diclofenac and tolbutamide, owing to its presence in a well-
known cocktail currently used in vivo in the clinical environ-
ment [11, 12]. Although certain authors have proposed a two-
site binding model for CYP3A activity and have recommend-
ed the use of two structurally unrelated probes [10], only
midazolam was included according to recent studies demon-
strating the evaluation of the in vitro CYP3A subfamily ac-
tivity, which was independent of the type and number of
substrates [13, 14].
The adjustment of the experimental conditions for the
cocktail, especially the incubation time and protein concen-
tration, was performed with the reference HLMs (pooled).
These incubation parameters were adjusted according to prac-
tical recommendations for the following reasons: (1) to avoid
excessive substrate depletion (less than 20 %) and (2) to
maintain a linear relationship between the amount of enzyme
or the incubation time and product formation [15, 16]. These
adjustments are challenging because the concentrations of the
individual CYPs in HLMs cannot be increased or decreased
separately because a constant ratio is maintained among the
different isoenzymes. When the reaction adjustment is based
on CYPs with low abundance in HLMs (e.g., CYP1A2,
CYP2C19, and CYP2D6), a higher protein concentration is
required to generate a detectable amount of the metabolite, but
this produces higher concentrations of the high-abundance
CYPs (e.g., CYP3A4 and CYP2C9), which negatively influ-
ence the kinetics from a linear to a nonlinear behavior. An
additional issue of higher microsomal protein concentrations
concerns the nonspecific binding to proteins and lipids (matrix
material) that can affect the reliability of the data [17]. In this
study, the reaction conditions, including the enzyme protein
concentration of 0.5 mg/mL and the incubation time of
20 min, were finally selected relative to the probe substrate
that presents the slowest turnover, (S)-mephenytoin
(CYP2C19). It has been shown elsewhere that the latter
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requires a longer incubation and a higher protein concentra-
tion to generate sufficient metabolite for detection [18]. As
depicted in Fig. 1, under these experimental conditions, the
in vitro recommendations were followed. As expected, sub-
strates (e.g., midazolam and coumarin) with a rapid turnover
and low Michaelis–Menten constants (Km) were highly de-
pleted, and their major metabolites were primarily formed
after 20 min. This incubation time exceeded the optimal
incubation time (15 min or less) to maintain the linearity of
1′-hydroxymidazolam and 7-hydroxycoumarin production
[19, 20]. Linear metabolite formation and low substrate dis-
appearance were followed for the other CYPs monitored.
Finally, these kinetic conditions were considered as acceptable
because the linear metabolite formation was followed for the
most of the CYPs, including the highly polymorphic CYPs
(CYP2C9, CYP2C19, and CYP2D6).
The concentrations of seven of the eight substrates were set
near or below their respective Km values (Table 1) for the
following reasons: (1) to maintain the high specificity of the
probe reaction, (2) to avoid or reduce potential interactions
among the substrates of the cocktail, and (3) to minimize the
percentage of organic solvent generally used for better sub-
strate solubility but that could significantly modify the CYP-
mediated metabolism [22]. Only the slow turnover probe (S)-
mephenytoin required its inclusion in the cocktail at a con-
centration higher than its Km to detect its metabolite. Prelim-
inary probe–probe interaction experiments showed that
bupropion (probe substrate for CYP2B6) interfered with the
activity of several CYPs, in particular that of CYP2C19.
Therefore, the concentration of bupropion was decreased to
less than 1/15 of the initial value. Hence, the observed inter-
action between this substrate and this isoform was reduced [a
s l i gh t i n c r e a s e o f CYP2C19-med i a t ed (± ) -4 ′ -
hydroxymephenytoin production], as reported elsewhere [20].
LC–MSE method
Considering the heterogeneous physicochemical properties of
the analytes studied, a generic gradient-based analytical
reversed-phase LC method was used to monitor the activities
of the eight CYP450 isoforms. With the cocktail developed,
the eight CYP probe substrates and their metabolites were
simultaneously analyzed in microsomal incubations, and are
listed in Table 1 along with the exact mass (m/z) and polarity
of the ESI used for the detection. The initial experiments were
performed to evaluate and optimize the ESI-MS response by
using both the positive mode and the negative mode and by
varying the cone voltages (fixed or ramped). Most of the
compounds showed good sensitivity in positive ionization
mode, except for chlorzoxazone/6-hydroxychlorzoxazone
and flurbiprofen/4′-hydroxyflurbiprofen, with sensitivities
that were significantly better in negative ionization mode. In
terms of absolute sensitivity (i.e., ion counts), the optimal cone
voltage was 30 V, regardless of the polarity chosen. As
depicted in Fig. 2, by use of a generic gradient LC separation,
all of the analytes were eluted with retention times ranging
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from 2 to 10.5min and were separated using the accurate mass
feature of the mass spectrometer (±0.02 Da, first function
MS). With use of the selected gradient, the substrate/
metabolite ion suppression effects were avoided because each
substrate was eluted after its respective metabolites. Low
chromatographic selectivity between midazolam and its me-
tabolite, 1′-hydroxymidazolam, was observed, along with cer-
tain critical selectivity windows for (S)-mephenytoin/dextro-
methorphan, phenacetin/coumarin/bupropion, and 7-
hydroxycoumarin/dextrorphan. However, because of the MS
dimensions, an overall resolution was obtained. To extract the
maximum information from the microsomal metabolism, a
multiresidue method that allows both quantitative and quali-
tative (MSE) analysis was considered. Compared with a clas-
sic time-of-flight MS acquisition, this detection mode
consisted of a first function (quantitative data) obtained in
the wide-pass quadrupole mode at a low fixed collision energy
(4 eV) and an alternated second function (qualitative data)
with a collision energy ramping from 20 to 35 eV. Combining
the MS/MS spectra obtained and postprocessing of the data
with automated software, one can reveal the complementary
metabolites that can potentially be formed.
Furthermore, in metabolism studies performed with the
cocktail substrates, the analytes are present in the incubation
sample over a wide range of concentrations. To overcome this
highly dynamic concentration range issue, which could lead to
incorrect exact mass measurements owing to the saturation of
the time-to-digital converter detector, a special feature, pDRE,
should be activated. In this case, an unattenuated and an
attenuated accumulation time are combined within the run to
generate a stitched data point where the measured mass could
be considered as exact. The combination of MSE and pDRE
significantly decreased the effective data acquisition rate of
the time-of-flight MS analyzer. With an accumulation time of
0.2 s (5 Hz, excluding the interscan delay), the effective
acquisition rate corresponded to approximately 0.8 s
(1.25 Hz). This value is not compatible with the very thin
peaks obtainedwith the narrow-bore column packedwith sub-
2-μm particles. Considering the effective acquisition rate,
sufficient data acquisition points (three points for each func-
tion) to achieve good quantitative data and MS data of suffi-
cient quality for reprocessing could not be obtained under the
optimal UHPLC conditions (0.04 min at 4.4 % of the peak
height at 600 μL/min). To address this constraint, a 100-mm
column packedwith larger particles (2.5μm)was used instead
of a shorter column (50 mm) packed with smaller particles
(1.7-μm particle inner diameter). With use of this configura-
tion, the following advantages were obtained: (1) the peak
width adapted to the data acquisition rate (0.11 min at 4.4 % of
the peak height at 400 μL/min), (2) equivalent chromato-
graphic performance (equivalent column length to particle
size ratio), (3) reduced extra-column broadening (higher col-
umn variance), (4) reduced backpressure (380 bar, which
corresponds to a decrease of approximately 40 %), and (5)
Table 1 The eight substrates selected for the cocktail approach, with their cytochrome P450 (CYP)-specific metabolites and exact detection mass
CYP isoform Probe substrate CYP-specific
reaction
CYP-specific metabolite Km
a
(μM)
Concentration for
incubation (μM)
Exact mass
(m/z)
Polarity
1A2 Phenacetin O-Deethylation 1.7-152 50 180.1024 ES+
Acetaminophen 152.0675 ES+
2A6 Coumarin 7-Hydroxylation 0.3-2.3 2 147.0446 ES+
7-Hydroxycoumarin 163.0395 ES+
2B6 Bupropion Hydroxylation 67-168 5 240.1155 ES+
Hydroxybupropion 238.0998 (−H2O) ES+
2C9 Flurbiprofen 4′-Hydroxylation 6-42 5 199.0923 (−COO) ES−
4′-Hydroxyflurbiprofen 215.0875 (−COO) ES−
2C19 (S)-Mephenytoin 4′-Hydroxylation 13-35 100 219.1134 ES+
(±)-4′-Hydroxymephenytoin 235.1083 ES+
2D6 Dextromethorphan O-Demethylation 0.4-8.5 5 272.2014 ES+
Dextrorphan 258.1858 ES+
2E1 Chlorzoxazone 6-Hydroxylation 39-157 40 167.9852 ES−
6-Hydroxychlorzoxazone 183.9801 ES−
3A subfamily Midazolam 1′-Hydroxylation 1-14 2.5 326.0860 ES+
1′-Hydroxymidazolam 342.0809 ES+
ES electrospray
a From [21]
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reduced flow rate (400 μL/min vs 600 μL/min). Compared
with the UHPLC conditions, the analysis time was increased
by a factor of 3, but the required sensitivity and an acceptable
number of data points (at least seven at 4.4 % of the peak
height) were obtained for correct peak shape generation with
both the MS function and the MSE function.
Fig. 2 Extracted ion chromatograms [of the first function mass spec-
trometry (MS), ±0.02 Da] of substrates and their CYP-specific metabo-
lites corresponding to the analysis of the cocktail microsomal incubation
(20 min). The peak highlighted with a cross results from an in-source MS
fragmentation (thermal degradation) of phenacetin in conditions used for
the analysis. ES electrospray, RT retention time, TOF time of flight
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Quantitative evaluation of the method
The selectivity of the LC–MSE method was confirmed by
injecting a series of blank samples as described in detail in
“Selectivity.” The extracted ion chromatograms (±0.02 Da)
for each analyte showed no major interferences at the corre-
sponding retention time. Response functions were considered
as linear (R2>0.95) over concentrations ranging from the
measured lower limit of quantification to 2,000 ng/mL, and
the method provided the desired sensitivity for each analyte.
As shown in Table 2, the response signal (peak area) of
some compounds was evaluated at three concentrations (low,
medium, and high) and was slightly affected (more than 25%)
by the matrix effect, particularly for the compounds with the
shortest retention times. However, this effect was corrected by
the use of the metabolic ratio as the analytical response. The
metabolic ratio, representing the CYP-specific metabolite to
probe substrate ratio, has often been used as a parameter for
in vivo and in vitro characterization of the activities of CYPs
instead of exclusive monitoring of the CYP probe metabolite
formation [23]. When the CYP-specific biotransformation is a
major pathway of the probe substrate, the metabolite and
substrate peak areas are closely correlated, and the metabolic
ratio will reflect the alteration of the isoform activity (e.g., the
presence of a genetic mutation).
The method precision of the LC–MSE method was then
estimated by triplicate injection of reconstituted mixtures of
substrates and metabolites on numerous analysis days, and the
variability obtained on the absolute peak area for each analyte
and for the CYP-specific metabolite to the probe substrate area
ratio are reported in Table 2. Considering the analytes indi-
vidually, the root mean square of the within-day variabilities
of the values presented ranges from 8.3 to 28.8 %. The
analytical variability was improved (within ±20 %) for all
the substrate and metabolite pairs using the absolute peak area
ratio, reducing the between-day variabilities to between 4.0
and 14.5 %.
Variability of the microsomal incubation method for as-
sessment of the CYP activities was then estimated on numer-
ous days by separately incubating different aliquots of the
pooled HLMs with the cocktail (freeze–thaw cycles). The
metabolic variability of the incubation method for the eight
CYP-specific probe substrates in pooled HLMs was within a
tolerance fixed at ±20 %. No significant batch or day effects
were observed on the activities of the CYPs, except for
CYP2D6 (day effect) and CYP3A (batch effect), whose var-
iability was less than 30 %. Considering these results, the
overall method showed the ability to generate reliable data
for estimation of the relative activities of the CYPs. It has to be
noted that in the case of a minor pathway, the metabolic ratio
is not sufficiently sensitive to reflect the activity of the mon-
itored CYP owing to the strong effect of substrate depletion
performed by other CYPs. Because the CYP-specific
biotransformations of the probe substrates selected for this
cocktail were major pathways, the metabolic ratio was an
appropriate value representing assessment of the in vitro ac-
tivities of the CYPs without absolute quantification of the
probe metabolites.
Comparison between the single-substrate and cocktail
approaches
To evaluate the potential interactions among the probes of the
cocktail, the CYP activities were compared using the meta-
bolic ratios obtained for the pooled HLMs, with the individual
substrates and the cocktail. For the latter, the presence of
multiple probes and metabolites in the incubation sample
could affect the activities of the CYPs and give an unrealistic
impression of the phase I metabolic capacity of the HLMs.
Considering that this type of HLM is a mixture of microsomes
prepared from several donors with normal CYP phenotypic
profiles, pooled HLMs possess the status of an average pa-
tient. The CYP phenotypic profiles obtained with the cocktail
approach and the classic approach are reported in Fig. 3a and
b, respectively. The measured ratios were over a range of four
orders of magnitude, and only the CYPs with high enzymatic
turnover (e.g., CYP2A6 and CYP3A) could be evidenced. For
clarity, the activities of the CYPs obtained using the cocktail
approach were considered as reference values (e.g., 100 % of
phase I activity). This reference profile could be represented
on an octagonal radar plot (Fig. 3c) in which each axis
corresponds to the relative activity of the CYP. The logarith-
mic scale affords equivalent visual variations in cases of
increasing and respective decreasing activities of the CYPs.
For example, an activity increased by a factor of 2 (i.e., 200%)
presents the same variation as that reduced by a factor of 2
(i.e., 50 %). When the two profiles are overlapped (Fig. 3d),
no significant differences are observed. The activities of all of
the CYPs were similar within 20 %, except for CYP2A6 and
CYP3A. The CYP2A6 activity was decreased by approxi-
mately 38 % in the cocktail assay, whereas the CYP3A activ-
ity was decreased by approximately 27 %, with both isoforms
generating lower metabolic ratios. For these isoforms, certain
interactions caused by the cocktail approach have been sug-
gested in the literature, which were not clearly identified [20,
24–26]. Although certain CYP activities decreased owing to
the inhibitory effect, the cocktail assay allowed the acquisition
of similar information in a single experiment about the CYP
phenotypic profile as the classic approach but using a smaller
amount of microsomes and proceeding eight times faster.
Determination and alteration of the CYP phenotypic profile
of allelic variant HLMs
The microsomal activities of the eight CYPs of allelic variants
CYP2C9*3/*3, CYP2C19*2/*2, and CYP2D6*4/*4 from
4882 D. Spaggiari et al.
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Phenotyping microsomal CYP450 by cocktail approach 4883
single human donors were selected to be characterized
with the cocktail assay developed. These HLM variants
were selected because they were affected by an important
genetic polymorphism, which significantly reduced the
activities of three major CYPs (CYP2C9, CYP2C19, and
CYP2D6) involved in the metabolism of major pharma-
ceutical drugs. The metabolic ratios of these single donors
were expressed as the percentage of the reference value
(pooled HLMs), and the normalized phenotypic profiles
are reported in Fig. 4. This representation of the micro-
somes presents certain advantages in terms of visual in-
terpretation. First, it demonstrates that the overall meta-
bolic capacity of the microsomes exhibits an important
interindividual variability. Then, in addition to the pres-
ence of genetic polymorphism [27], the three single-donor
microsomes show three very different CYP phenotypic
profiles. The results for each single-donor allelic variant
HLM were in complete agreement with the genetic poly-
morphism and each exhibited reduced enzymatic activity
for the CYP concerned compared with the activity
expressed in normal pooled HLMs.
In addition to genetic variability (polymorphism), the CYP
activities can be inhibited or induced by drugs. Two of the
most significant enzymes participating in marketed drug me-
tabolism, i.e., CYP2D6 and the CYP3A subfamily (especially
CYP3A4) [28], are often involved in DDI.
The alteration of the activities of these CYPs and of the
phenotypic profile was then studied for the allelic variant
CYP2D6*4/*4 HLMs. Chemical competitive inhibitors and
baculosome CYP2D6 were sequentially incubated with the
CYP2D6*4/*4 HLMs to demonstrate the capability of the
cocktail approach to show evidence of the metabolism mod-
ification. As expected and as depicted in Fig. 5a, the addition
of quinidine (1 μM), a CYP2D6 selective inhibitor, did not
modify the overall microsomal phenotype. Owing to the very
low initial activity of this allelic variant isoform (i.e., CYP2D6
was already affected by genetic polymorphism), the effect of
this potent inhibitor is negligible. The specificity of this inhib-
itor at 1 μMwas confirmed by the similar profiles of the CYP
activities and the noninhibited system (Fig. 4c).
Then, to improve the reduced CYP activity in the same
polymorphic HLMs, this system was exposed to baculosome
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Fig. 3 Classic representation of CYP phenotypic metabolic profiles of
pooled HLMs obtainedwith the cocktail approach (a) and with the classic
approach (individual incubations of substrates) (b). Histograms showing
absolute metabolic ratios for the activities of the eight CYPs. Alternative
representation of CYP phenotypic profiles of pooledHLMs obtainedwith
the cocktail approach (c) and with the classic approach (d). The radar
chart in c reports the metabolic ratios expressed as the reference profile
(100 %), whereas the radar chart in d shows the overlapping of the
reference profile and the profile obtained with the classic approach
expressed as a percentage of the reference
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CYP2D6 (3 nM). As shown in Fig. 5b, the polymorphic
HLMs recovered the CYP2D6 metabolic activity after addi-
tion of the functional isoform without modifying the overall
phase I metabolic capacity.
The addition of ketoconazole, a CYP3A selective inhibitor,
at a concentration of 1 μM reduced the CYP3A activity,
whereas the activities of the other CYPs monitored were not
modified compared with the original profile (Fig. 5c), which
confirms the high specificity of ketoconazole at this
concentration.
QTOF data for the extension of the CYP phenotypic profile
As previously mentioned, the cocktail phase I metabolism
is very complex owing to the large number of substrates and
the simultaneous presence of all of the hepatic isoforms of
the CYPs in the HLMs. Each substrate generates specific
metabolites, but these metabolites could be substrates, cre-
ating a second generation of phase I metabolites. Therefore,
the number of features to potentially monitor will increase
with the number of probes in the cocktail. In this context,
QTOF-MS acquisition, which does not require prior selec-
tion of the metabolites to be detected, could be advanta-
geously applied. Indeed, known metabolites can be accu-
rately extracted with the exact mass and narrow mass win-
dow (e.g., Fig. 2), whereas unknown metabolites can also
be detected and identified using automated software (e.g.,
Metabolynx™). Two simple examples of this concept are
shown in Fig. 6. In addition to 1′-hydroxylation, the
CYP3A subfamily catalyzes to a minor extent the 4-
hydroxylation of midazolam (Fig. 6a) [29]. The resulting
metabolite has the same mass as the major metabolite, but it
has a different retention time, as depicted in Fig. 2. The
modification of the CYP3A activity, expressed as the met-
abolic ratio of 4-hydroxymidazolam to midazolam in allelic
variant CYP2D6*4/*4 HLMs, was in complete agreement
with the alterations and was very close to that obtained for
the major metabolite. As shown in Fig. 6b, the enzyme
isoforms involved in the overall metabolism of dextrome-
thorphan are CYP2D6, responsible for the O-demethylation
to dextrorphan, and CYP3A, which mediates the N-
demethylation to 3-methoxymorphinan. The specificity of
CYP3A is high, but Km for this pathway is 100 times higher
than for O-demethylation, making it a minor metabolic
pathway [10]. Extraction of 3-methoxymorphinan occurs
at the same mass as dextrorphan, and has a retention time of
6.33 min (Fig. 2). As depicted in Fig. 6b, the modification
of the CYP3A activity, expressed as the metabolic ratio of
3-methoxymorphinan to dextromethorphan in allelic vari-
ant CYP2D6*4/*4 HLMs, showed results similar to those
obtained considering both of the midazolam metabolites.
The addition of quinidine or baculosome CYP2D6 did not
affect the ratio representing this CYP3A-mediated biotrans-
formation. As expected, the addition of ketoconazole de-
creased the CYP3A activity. The significantly lower affin-
ity of dextromethorphan for CYP3A could explain the
lower effect of ketoconazole on the CYP3A activity com-
pared with midazolam.
Finally, these biotransformations could be integrated as a
supplementary assessment of the CYP3A activity and, con-
sidering that each CYP isoform can potentially be involved in
the formation of known and unknown metabolites from dif-
ferent substrates, a more precise phenotypic profile of the
CYPs (e.g., “extended cocktail profile”) could be generated
using QTOF-MS by extracting the latent metabolic
information.
Conclusion
A cocktail assay including eight probe substrates was devel-
oped to simultaneously phenotype the eight major CYPs in
HLMs. The CYP activities were evaluated on the basis of the
metabolic ratio measured using the LC–MSE method. Sepa-
ration of the analytes was performed on a 10-cm column
packed with 2.5-μm particles, which primarily allowed the
acquisition of a suitable chromatographic peak width compat-
ible with the low acquisition rate generated by the MSE and
pDRE association. This type of detection method made
A B C
HLM with CYP2C9*3/*3 HLM with CYP2C19*2/*2 HLM with CYP2D6*4/*4
Fig. 4 Determination of CYP
phenotypic profile with the
cocktail approach. Application to
single-donor polymorphic HLMs:
a CYP2C9*3/*3; b CYP2C19*2/
*2; and c CYP2D6*4/*4. CYP
metabolic ratios are expressed as
a percentage of the metabolic
ratios obtained with pooled
HLMs (100 %)
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possible the simultaneous acquisition of good quantitative and
qualitative data with an enhanced dynamic range and im-
proved mass accuracy measurements. The variability of the
analytical method was improved using the metabolic ratio,
which avoided the use of an additional analytical standard in
the quenching solution. Owing to the good analytical variabil-
ity, it was possible to use this parameter as an indicator of the
CYP activity without performing absolute quantification.
Time-based investigations on cocktail metabolism in
pooled HLMs defined 20 min as the optimal incubation time,
which corresponds to a compromise between linearity of
metabolite formation and acceptable substrate depletion. Un-
der these conditions, the low enzymatic turnover substrate (S)-
mephenytoin generated a detectable amount of CYP-specific
metabolite, allowing the assessment of the highly polymor-
phic CYP2C19 activity.
The reliability of the cocktail assay was confirmed after
comparison with individual incubations of the substrates,
which generated similar results. The CYP phenotypic profile
resulted in the following: (1) better understanding of the
A B C
HLM with CYP2D6*4/*4 
+ quinidine 1µM
HLM with CYP2D6*4/*4
+ ketoconazole 1µM
HLM with CYP2D6*4/*4
+ baculosome CYP2D6 3nM
Fig. 5 CYP phenotypic profile of
single-donor polymorphic HLMs
(CYP2D6*4/*4) modified with
1 μM quinidine (a), 3 nM
baculosome CYP2D6 (b), and
1 μM ketoconazole (c), obtained
with the cocktail approach. CYP
metabolic ratios are expressed as
a percentage of the metabolic
ratios obtained with pooled
HLMs (100 %)
A B
Fig. 6 a Microsomal phase I metabolism of midazolam (I). The metab-
olites are 1′-hydroxymidazolam (II) and 4-hydroxymidazolam (III). The
histogram at the bottom represents the CYP3A activity of single-donor
polymorphic HLMs (CYP2D6*4/*4) modified with 1 μM quinidine, 3
nM baculosome CYP2D6, or 1 μM ketoconazole, using CYP3A-medi-
ated 4-hydroxylation of midazolam. CYP metabolic ratios (4-hydroxy-
midazolam to midazolam) are expressed as a percentage (mean±range,
n=2) of the metabolic ratio obtained with no altered CYP2D6*4/*4
HLMs (100 %). bMicrosomal phase I metabolism of dextromethorphan
(I). The metabolites are dextrorphan (II), 3-methoxymorphinan (III), and
3-hydroxymorphinan (IV). The histogram at the bottom represents the
CYP3A activity of single-donor polymorphic HLMs (CYP2D6*4/*4)
modified with 1 μM quinidine, 3 nM baculosome CYP2D6, or 1 μM
ketoconazole, using CYP3A-mediated N-demethylation of dextrome-
thorphan to 3-methoxymorphinan. CYP metabolic ratios (3-
methoxymorphinan to dextromethorphan) are expressed as a percentage
(mean ± range, n=2) of the metabolic ratio obtained with no altered
CYP2D6*4/*4 HLMs (100 %)
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overall metabolic capacity of the microsomes tested, (2) com-
parison between profiles, and (3) an easily observable demon-
stration of the modifications of the CYP activities. Conse-
quently, this cocktail assay was shown to be useful for phase
I microsomal metabolism characterization and to rapidly high-
light xenobiotics with a significant effect on the activities of
CYPs, which is helpful during screening experiments. In com-
bination with more sophisticated in vitro methods and/or with
the assistance of in vitro-based computational simulation of
in vivo data, this cocktail approach may be the first step toward
filling the existing gap between in vitro and in vivo data.
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